2,403
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Avelumab: is it time to get excited?

, &
Pages 815-821 | Received 19 Jan 2018, Accepted 22 Jun 2018, Published online: 02 Jul 2018
 

Declaration of interest

H Kaufman is an employee of Replimune Inc. and has served on advisory boards for Merck KGaA/EMD Serono. J Gulley has served on advisory boards for EMD Serono, although participated in this project as part of his official duties for the U.S. federal government and received no compensation from EMD Serono. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This manuscript has not been funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.